Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCC Warrior Met Coal LLC

Post-Market Trading 05-16 19:52:10 EDT

63.79

+0.27

+0.43%

盘后62.50

-1.29-2.02%

16:55 EDT

High64.10	Low62.59	Vol509.63K
Open63.55	D1 Closing63.52	Amplitude2.38%
Mkt Cap3.34B	Tradable Cap3.27B	Total Shares52.30M
T/O32.46M	T/O Rate0.99%	Tradable Shares51.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":63.79,"timestamp":1715889600000,"preClose":63.52,"halted":0,"volume":509629,"hourTrading":{"tag":"盘后","latestPrice":62.5,"preClose":63.79,"latestTime":"16:55 EDT","volume":15655,"amount":998627.4404,"timestamp":1715892926063},"delay":0,"floatShares":51321146,"shares":52300707,"eps":8.314237,"marketStatus":"Post-Market Trading","change":0.27,"latestTime":"05-16 19:52:10 EDT","open":63.55,"high":64.1,"low":62.59,"amount":32455468.0505,"amplitude":0.023772,"askPrice":65.58,"askSize":150,"bidPrice":63.31,"bidSize":2,"shortable":3,"etf":0,"ttmEps":8.314237,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1715904000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":63.52,"dividendRate":0.004546,"preHourTrading":{"tag":"盘前","latestPrice":64.07,"preClose":63.52,"latestTime":"08:19 EDT","volume":327,"amount":20785.890378,"timestamp":1715861998509},"postHourTrading":{"tag":"盘后","latestPrice":62.5,"preClose":63.79,"latestTime":"16:55 EDT","volume":15655,"amount":998627.4404,"timestamp":1715892926063},"volumeRatio":0.914629},"requestUrl":"/m/hq/s/HCC/wiki","defaultTab":"wiki","newsList":[{"id":"2435542671","title":"Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435542671","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2435542671?lang=en_us&edition=fundamental","pubTime":"2024-05-16 12:00","pubTimestamp":1715832000,"startTime":"0","endTime":"0","summary":"Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC mee","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/16/2883354/0/en/Replimune-Reports-Fiscal-Fourth-Quarter-and-Year-Ended-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435361936","title":"Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2435361936","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2435361936?lang=en_us&edition=fundamental","pubTime":"2024-05-15 18:45","pubTimestamp":1715769900,"startTime":"0","endTime":"0","summary":"New Phase 3 data evaluating sacituzumab tirumotecan , an investigational TROP2-directed antibody-drug conjugate, in previously treated locally recurrent or metastatic triple-negative breast cancer. First presentation of Phase 2b three-year follow-up data evaluating mRNA-4157 , an investigational individualized neoantigen therapy, in combination with KEYTRUDA  in patients with high-risk stage III/IV melanoma following complete resection. Three-year follow-up data from the Phase 3 KEYNOTE-966 study evaluating KEYTRUDA plus chemotherapy versus chemotherapy alone for patients with advanced biliary tract cancer  .Longer-term follow-up results from the Phase 3 KEYNOTE-859 study evaluating KEYTRUDA plus chemotherapy versus chemotherapy alone for advanced human epidermal growth factor receptor 2 -negative gastric or gastroesophageal junction cancer .Health-related quality of life  data from the Pha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZX4fg7BGRm1fPi47l4.Hvg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/382bf33f895ddf3ce2507035c988fc15","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZX4fg7BGRm1fPi47l4.Hvg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/382bf33f895ddf3ce2507035c988fc15"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-present-data-2024-asco-104500141.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435068433","title":"Bear of the Day: Peabody Energy (BTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435068433","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435068433?lang=en_us&edition=fundamental","pubTime":"2024-05-15 16:00","pubTimestamp":1715760000,"startTime":"0","endTime":"0","summary":"Zacks Rank #5  stock Peabody Energy  is a preeminent coal producer engaged in the mining, processing, and the sale of coal through 17 operations, mainly in the United States and Australia. Peabody Energy mostly mines and processes thermal coal, which is utilized for power generation, and metallurgical coal, which is utilized in steel production.In 2020, Coal stocks like BTU, Arch Resources , and Warrior Met Coal  were on the brink of collapse as demand plummeted due to the COVID-19 pandemic, and investor concerns about investors attempting to replace the entire industry with clean energy alternatives. Since then, several coal companies have gone bankrupt. Nevertheless, the ones that survived enjoyed recovering earnings and soaring stock prices.However, despite the impressive recovery in coal demand, the International Energy Agency  sees global coal demand leveling off and cooling over the next few years and into 2026. The late 2023 report marks the first time the IEA has predicted a dr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JnLacEvA5XnVZWK3HOf78w--~B/aD0yMTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/edb62b5bd2d92f378f3a3eee31f7e50c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JnLacEvA5XnVZWK3HOf78w--~B/aD0yMTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/edb62b5bd2d92f378f3a3eee31f7e50c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bear-day-peabody-energy-btu-080000876.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435401303","title":"Third Avenue Management Boosts Stake in Lazard Inc, Highlighting Strategic Portfolio Adjustments","url":"https://stock-news.laohu8.com/highlight/detail?id=2435401303","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2435401303?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:02","pubTimestamp":1715619727,"startTime":"0","endTime":"0","summary":"Insight into the First Quarter Moves of 2024 by Third Avenue Management . GuruFocus has detected 5 Warning Sign with TDW.Founded by the legendary value investor Martin Whitman, Third Avenue Management  is renowned for its disciplined investment approach, focusing on deep value and distressed assets. Since its inception, the firm has expanded its expertise across various strategies including Value, Small-Cap, Real Estate, and International Real Estate. Partnering with Affiliated Managers Group since 2002, Third Avenue has enhanced its governance structure, ensuring long-term stability and alignment with investors' interests. The firm's latest 13F filing for the first quarter of 2024 reveals significant portfolio adjustments, underscoring its strategic investment decisions.Lazard Inc , purchasing 550,472 shares. This addition makes up 3.68% of the portfolio, with a total value of $23.05 million.As of the first quarter of 2024, Third Avenue Management 's portfolio comprises 58 stocks. The","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9ebLzpiQu.13jfbsE0ZNAA--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/5213c2fec7e85e911d60baee14242e63","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9ebLzpiQu.13jfbsE0ZNAA--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/5213c2fec7e85e911d60baee14242e63"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/third-avenue-management-boosts-stake-170207967.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435343326","title":"Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2435343326","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2435343326?lang=en_us&edition=fundamental","pubTime":"2024-05-13 19:00","pubTimestamp":1715598000,"startTime":"0","endTime":"0","summary":"Can-Fite has received agreement from both the U.S. Food and Drug Administration  and European Medicines Agency  on the current pivotal Phase 3 clinical study. RAMAT GAN, Israel, May 13, 2024----Can-Fite BioPharma Ltd.  , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that it held a conference for 75 oncologists and coordinators who are conducting the pivotal Phase 3 advanced liver cancer study, to accelerate patient enrolment.Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor . Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease  and non-alcoholic steatohepatitis . A3AR","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rBaWTJ1YgYLTHH53uCJTTA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c55f7e17af96491471ca06b389c206cf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rBaWTJ1YgYLTHH53uCJTTA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c55f7e17af96491471ca06b389c206cf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-75-oncologists-coordinators-europe-110000599.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435325190","title":"Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2435325190","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2435325190?lang=en_us&edition=fundamental","pubTime":"2024-05-13 18:45","pubTimestamp":1715597100,"startTime":"0","endTime":"0","summary":"RAHWAY, N.J., May 13, 2024----Merck , known as MSD outside of the United States and Canada, today announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab , Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma . At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival  met the pre-specified futility criteria. A higher rate of discontinuation of all adjuvant therapy by patients in the coformulation arm versus the KEYTRUDA-only arm, primarily due to immune-mediated adverse experiences, rendered it highly unlikely that the trial could achieve a statistically significant improvement in RFS. Based on the recommendation of an independent Data Monitoring Committee , Merck is unblinding the study and recommends t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g..Bc9UW4V0QMeGXoZq_0g--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e3f533a6c1380fea27b3710161fbd2aa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g..Bc9UW4V0QMeGXoZq_0g--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e3f533a6c1380fea27b3710161fbd2aa"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-provides-phase-3-keyvibe-104500620.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434812857","title":"Analysts Have Conflicting Sentiments on These Materials Companies: Artemis Gold (OtherARGTF), Warrior Met Coal (HCC) and Coeur Mining (CDE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434812857","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434812857?lang=en_us&edition=fundamental","pubTime":"2024-05-11 10:02","pubTimestamp":1715392943,"startTime":"0","endTime":"0","summary":"Companies in the Materials sector have received a lot of coverage today as analysts weigh in on Artemis Gold (ARGTF – Research Report), Warrior Met...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-materials-companies-artemis-gold-otherargtf-warrior-met-coal-hcc-and-coeur-mining-cde?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-materials-companies-artemis-gold-otherargtf-warrior-met-coal-hcc-and-coeur-mining-cde?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434789902","title":"Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2434789902","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434789902?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:30","pubTimestamp":1715373000,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., May 10, 2024----Bristol Myers Squibb  today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival  in unresectable, locally advanced stage III non-small cell lung cancer . CheckMate -73L evaluated Opdivo  with concurrent chemoradiotherapy  followed by Opdivo plus Yervoy  versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC. The observed adverse events of Opdivo with CCRT followed by Opdivo plus Yervoy were generally consistent with the known profiles of each component in the regimen.\"Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve PFS outcomes in this setting,\" said Joseph Fiore, vice president, global program lead, thoracic cancers, Bristol Myers Squibb. \"There remains a critical need to improve long-term outcomes for these patients and we believe these results will help inform future drug development efforts in this setting. We want to thank","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kT27rt97WB90AbSvWod9tQ--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b9f2f19aa76442516248a37f92f8c4b2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kT27rt97WB90AbSvWod9tQ--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b9f2f19aa76442516248a37f92f8c4b2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-provides-phase-203000444.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434859819","title":"Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2434859819","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2434859819?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:00","pubTimestamp":1715346000,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd.  and Nutriband Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Can-Fite BioPharma Ltd.  is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tLlOAj8dEftABEEyuua9Bg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/dfb0cf442592690230acaf832878a24e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tLlOAj8dEftABEEyuua9Bg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/dfb0cf442592690230acaf832878a24e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-biopharma-nutriband-interviews-air-130000037.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434093634","title":"Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2434093634","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434093634?lang=en_us&edition=fundamental","pubTime":"2024-05-09 19:00","pubTimestamp":1715252400,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, May 09, 2024----Can-Fite BioPharma Ltd.  , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that the U.S. Food and Drug Administration  has granted Investigational New Drug  clearance for Namodenoson, for the treatment of patients with metabolic dysfunction-associated steatohepatitis , also known as non-alcoholic steatohepatitis , for the Company’s ongoing Phase IIb clinical study.Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor . Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcohol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vlPqizZ_oZ6S8PouWiPMRQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d5ba21b96ad2adc2ab665a23beffde8b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vlPqizZ_oZ6S8PouWiPMRQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d5ba21b96ad2adc2ab665a23beffde8b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-fda-grants-ind-clearance-110000893.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434093855","title":"Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent","url":"https://stock-news.laohu8.com/highlight/detail?id=2434093855","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434093855?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:45","pubTimestamp":1715251500,"startTime":"0","endTime":"0","summary":"RAHWAY, N.J., May 09, 2024----Merck , known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival  for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent.Merck has a comprehensive clinical development program in endometrial carcinoma, including the NRG-GY018/KEYNOTE-868 trial evaluating KEYTRUDA in combination with standard of care chemotherapy , followed by KEYTRUDA as a single agent for th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uB7Hgq5tgP7pP2mMwXObpg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ae251c5c808b6a812db9d865d680b6b4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uB7Hgq5tgP7pP2mMwXObpg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ae251c5c808b6a812db9d865d680b6b4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-provides-phase-3-keynote-104500563.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433424343","title":"Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424343","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433424343?lang=en_us&edition=fundamental","pubTime":"2024-05-06 19:00","pubTimestamp":1714993200,"startTime":"0","endTime":"0","summary":"Patent has already been issued in other major markets including the U.S.PETACH TIKVA, Israel, May 06, 2024----Can-Fite BioPharma Ltd.  , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the European Patent Office for its patent application titled \"An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction\". This invention addresses the use of the CF602 drug candidate as an oral or topical drug for patients such as diabetics, who suffer from erectile dysfunction, and cannot use the current drugs on the market.Can-Fite BioPharma Ltd.   is an advanced clinical stage drug development Company with a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/m9xcONbf.QO.6AMJFD8K0A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4137538c3fb6c0b858edceca42ab3d1a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/m9xcONbf.QO.6AMJFD8K0A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4137538c3fb6c0b858edceca42ab3d1a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-received-notice-allowance-european-110000150.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433426392","title":"European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...","url":"https://stock-news.laohu8.com/highlight/detail?id=2433426392","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433426392?lang=en_us&edition=fundamental","pubTime":"2024-05-06 18:59","pubTimestamp":1714993140,"startTime":"0","endTime":"0","summary":"Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy. European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo  Plus Yervoy  for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer. Bristol Myers Squibb  today announced that the European Medicines Agency  has validated its Type II variation application for Opdivo  plus Yervoy  for the first-line treatment of adult patients with microsatellite instability–high  or mismatch repair deficient  metastatic colorectal cancer . The EMA’s validation of the application confirms the submission is complete and begins the EMA’s centralized review process.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tsm9SX3pqC3RS_tNWupIiw--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/97daf3748d612e5785729b7d091fb25a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tsm9SX3pqC3RS_tNWupIiw--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/97daf3748d612e5785729b7d091fb25a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-validates-bristol-105900474.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433263974","title":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433263974","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433263974?lang=en_us&edition=fundamental","pubTime":"2024-05-06 18:59","pubTimestamp":1714993140,"startTime":"0","endTime":"0","summary":"Application based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of nivolumab to evaluate and demonstrate noninferior pharmacokinetics, efficacy and consistent safety vs. its intravenous formulation. Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor. The FDA assigned a target action date of February 28, 2025. \"We believe subcutaneous nivolumab has the potential to make a significant difference in the lives of patients, which is reinforced by the FDA’s acceptance of our application,\" said Gina Fusaro, Ph.D., vice president, global program lead, Bristol Myers Squibb. \"Opdivo is a foundational PD-1 inhibitor approved for many different types of cancer, and our continued investment in research that puts patients first remains a priority. If approved by the FDA, the subcutaneous administration of nivolumab would provide patients and their physicians with a new option that delivers the same well-k","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CpxSCnRdUrT1cx0nl8c3AA--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a4e032c7ee2fb10fd0e4af537f70ce32","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CpxSCnRdUrT1cx0nl8c3AA--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a4e032c7ee2fb10fd0e4af537f70ce32"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-accepts-105900988.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433522425","title":"Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2433522425","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2433522425?lang=en_us&edition=fundamental","pubTime":"2024-05-06 11:00","pubTimestamp":1714964400,"startTime":"0","endTime":"0","summary":"Advanced MYCHELANGELO I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/06/2875692/0/en/Omega-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432143859","title":"Warrior Met Coal, Inc. Just Recorded A 5.6% Revenue Beat: Here's What Analysts Think","url":"https://stock-news.laohu8.com/highlight/detail?id=2432143859","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432143859?lang=en_us&edition=fundamental","pubTime":"2024-05-04 20:37","pubTimestamp":1714826249,"startTime":"0","endTime":"0","summary":"Shareholders might have noticed that Warrior Met Coal, Inc.  filed its first-quarter result this time last week. The early response was not positive, with shares down 5.6% to US$66.23 in the past week. It was a workmanlike result, with revenues of US$504m coming in 5.6% ahead of expectations, and statutory earnings per share of US$2.62, in line with analyst appraisals. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.The most important thing to take away is that the analysts downgraded their earnings p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w2t1xoPraquUCzh5JCiwDw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/073fc6331af6400e3dbbb4524a7bb84d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w2t1xoPraquUCzh5JCiwDw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/073fc6331af6400e3dbbb4524a7bb84d"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/warrior-met-coal-inc-just-123729212.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432499928","title":"Warrior Met Coal Outperforms in Q1 2024, Analysts Favor Low-Cost Players","url":"https://stock-news.laohu8.com/highlight/detail?id=2432499928","media":"WallStreetZen","top":-1,"share":"https://ttm.financial/m/news/2432499928?lang=en_us&edition=fundamental","pubTime":"2024-05-03 16:18","pubTimestamp":1714724280,"startTime":"0","endTime":"0","summary":"B. Riley Securities's Lucas Pipes raised their price target on Warrior Met Coal (NYSE: HCC) by 4.6% from $87 to $91 on 2024/05/02. The analyst maintained their Strong Buy rating on the stock.After ass","market":"us","thumbnail":"https://images.unsplash.com/photo-1560713269-4e9527797b8f?crop=entropy&cs=tinysrgb&fit=crop&fm=jpg&ixid=M3w0NDY2OTN8MHwxfGFsbHx8fHx8fHx8fDE3MTI5MDE2NDR8&ixlib=rb-4.0.3&q=80&w=260&utm_source=wallstreetzen&utm_medium=referral&utm_campaign=api-credit&h=180","type":0,"news_type":0,"thumbnails":["https://images.unsplash.com/photo-1560713269-4e9527797b8f?crop=entropy&cs=tinysrgb&fit=crop&fm=jpg&ixid=M3w0NDY2OTN8MHwxfGFsbHx8fHx8fHx8fDE3MTI5MDE2NDR8&ixlib=rb-4.0.3&q=80&w=260&utm_source=wallstreetzen&utm_medium=referral&utm_campaign=api-credit&h=180"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.wallstreetzen.com/news/warrior-met-coal-outperforms-in-q1-2024-analysts-favor-low-cost-players","is_publish_highlight":false,"gpt_icon":0},{"id":"2432193600","title":"Warrior Met Coal Is Maintained at Market Perform by BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2432193600","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432193600?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:33","pubTimestamp":1714660380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HCC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 02, 2024 10:33 ET (14:33 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432605343","title":"Warrior Met Coal Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2432605343","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432605343?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:58","pubTimestamp":1714654727,"startTime":"0","endTime":"0","summary":"* Warrior Met Coal Inc    reported quarterly adjusted earnings of $2.63 per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of $3.57.  The me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432718346","title":"Q1 2024 Warrior Met Coal Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2432718346","media":"Thomson Reuters StreetEvents","top":-1,"share":"https://ttm.financial/m/news/2432718346?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:16","pubTimestamp":1714648580,"startTime":"0","endTime":"0","summary":"Walter Scheller; Chief Executive Officer, Director; Warrior Met Coal Inc. Thanks, operator. Hello, everyone, and thank you for taking the time to join us today to discuss our first quarter 2024 results. After my remarks, Dale will review our results in additional detail, then you'll have the opportunity to ask questions.We delivered very strong results for the first quarter, driven by our operational performance. The volume of steelmaking coal that we produce reached levels not seen since 2020. We took advantage of the inventory levels we had built over the preceding quarters to generate over $104 million in cash from operations, which we primarily used to invest in our Blue Creek growth project and returning additional cash to stockholders.We also made excellent progress on Blue Creek meeting several key milestones as we advance the development of this world-class growth projects that has the potential to transform our company.First, let me provide an overview of the steel and steelma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q1-2024-warrior-met-coal-111620614.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.warriormetcoal.com","stockEarnings":[{"period":"1week","weight":-0.0201},{"period":"1month","weight":0.0111},{"period":"3month","weight":0.0805},{"period":"6month","weight":0.1807},{"period":"1year","weight":0.7778},{"period":"ytd","weight":0.0418}],"compareEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0502},{"period":"3month","weight":0.0553},{"period":"6month","weight":0.1752},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.1146}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.063019},{"month":2,"riseRate":0.571429,"avgChangeRate":0.001096},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.052653},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.008197},{"month":5,"riseRate":0.375,"avgChangeRate":0.010908},{"month":6,"riseRate":0.714286,"avgChangeRate":0.022957},{"month":7,"riseRate":0.714286,"avgChangeRate":0.065818},{"month":8,"riseRate":0.428571,"avgChangeRate":0.015321},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032899},{"month":10,"riseRate":0.571429,"avgChangeRate":0.043658},{"month":11,"riseRate":0.571429,"avgChangeRate":0.066325},{"month":12,"riseRate":0.857143,"avgChangeRate":0.089824}],"exchange":"NYSE","name":"Warrior Met Coal LLC","nameEN":"Warrior Met Coal LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Warrior Met Coal LLC,HCC,Warrior Met Coal LLC股票,Warrior Met Coal LLC股票老虎,Warrior Met Coal LLC股票老虎国际,Warrior Met Coal LLC行情,Warrior Met Coal LLC股票行情,Warrior Met Coal LLC股价,Warrior Met Coal LLC股市,Warrior Met Coal LLC股票价格,Warrior Met Coal LLC股票交易,Warrior Met Coal LLC股票购买,Warrior Met Coal LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction